On Sept. 14, 2021, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), awarded two contract modifications totaling $3.2 billion to Regeneron Pharmaceuticals, Inc. and Eli Lilly and Company to purchase additional doses of monoclonal antibodies to block the infectivity of SARS-CoV-2, the virus that causes COVID-19.
DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, Army Contracting Command, and HHS’ Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, led these efforts. The efforts were funded by BARDA through the American Rescue Plan Act to supply critical medical resources to the nation.
DOD Awards $2.9 Billion Contract Modification to Regeneron Pharmaceuticals, Inc. to Purchase Additional Doses of REGEN-COV
DOD awarded a $2.9 billion contract modification to Regeneron Pharmaceuticals, Inc., to purchase additional doses of REGEN-COV, which combines two monoclonal antibodies, casirivimab and imdevimab, to block the infectivity of SARS-CoV-2. REGEN-COV, currently available under a Food and Drug Administration (FDA) Emergency Use Authorization (EUA), is used to treat infected patients to reduce risk of hospitalization or death from COVID-19, and for post-exposure prophylaxis for close contacts of infected individuals. Regeneron will begin delivery of the additional 1.4 million doses in September 2021, completing delivery by January 2022.
DOD Awards $329.8 Million Contract Modification to Eli Lilly and Company to Purchase Additional Doses of Etesevimab
DOD awarded a $329.8 million contract modification to Eli Lilly and Company, headquartered in Indianapolis, Indiana, to purchase additional doses of etesevimab. Etesevimab, also currently under an FDA EUA, is used together with bamlanivimab to treat people with COVID-19. Eli Lilly will begin delivery of the additional 388,000 doses in September 2021, completing delivery by November 2021.